Ser254
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser254  -  LEO1 (human)

Site Information
DDERPQAsDEEHRHs   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 7102562

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 )
Disease tissue studied:
breast cancer ( 1 )
Relevant cell line - cell type - tissue:
HeLa (cervical) ( 3 ) , Jurkat (T lymphocyte) ( 2 ) , MCF-7 (breast cell) ( 1 )

References 

1

Carrier M, et al. (2016) Phosphoproteome and Transcriptome of RA-Responsive and RA-Resistant Breast Cancer Cell Lines. PLoS One 11, e0157290
27362937   Curated Info

2

Guo A (2011) CST Curation Set: 12077; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pTDXEAntibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) CK2 Substrate (P-S/T3-100) Rabbit mAb Cat#: 8738
Curated Info

3

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info